Application of probiotic yeast microcapsules in drugs for treating immune diseases related to macrophage immunoregulation

By directly targeting macrophages with yeast microcapsules, the problems of low bioavailability and poor targeting of RA therapeutic drugs are solved, and efficient immunomodulation and safe therapeutic effects are achieved, simplifying the preparation process and reducing side effects.

CN119280287APending Publication Date: 2025-01-10SECOND AFFILIATED HOSPITAL OF COLLEGE OF MEDICINEOF XIAN JIAOTONG UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411410712.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2025-01-10

AI Technical Summary

Technical Problem

Existing RA therapeutic drugs have problems such as low bioavailability, high trauma, poor targeting and low patient compliance. Traditional oral drugs are difficult to specifically target macrophages, resulting in limited efficacy and in the gastrointestinal environment. poor stability and easy to be degraded or inactivated.

Method used

Probiotic yeast microcapsules are used as oral drug itself, and yeast microcapsules are prepared through acid-base treatment and chemical reagent extraction, directly targeting macrophages, using β-glucan on the surface of yeast microcapsules and Dectin on the surface of macrophages. -1 receptor binding to achieve targeted and immune regulation.

Benefits of technology

Improves the targeting and therapeutic effect of drugs, simplifies the preparation process, reduces potential adverse reactions and side effects, significantly improves the simplicity and safety of treatment, provides new drug delivery routes and dosage form options, suitable for long-term treatment patients with immune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119280287A_ABST
    Figure CN119280287A_ABST
Patent Text Reader

Abstract

The invention discloses application of probiotic yeast microcapsules in drugs for targeted regulation of inflammatory macrophage immunity, and belongs to the technical field of biological medicines. As a novel medicine, the yeast microcapsule has the characteristics of engineering, convenience, low cost, high patient compliance, high safety and excellent targeting property, can be used as an oral medicine for treating chronic inflammatory disease rheumatoid arthritis, acts on mitochondria through oxidative stress and oxidative phosphoric acid pathways, inhibits excessive activation of macrophages, and has the effect of treating chronic inflammatory disease rheumatoid arthritis. Release of inflammatory factors is reduced, and inflammatory reaction is relieved; the yeast micro-capsule can promote the phagocytosis and antigen presentation function of macrophages and enhance the immune defense capability of a body, so that the immune function of the macrophages is adjusted, and the yeast micro-capsule shows huge potential in preparation of drugs for targeted adjustment of inflammatory macrophage immunity, and has a broad application prospect in preparation of drugs for targeted adjustment of inflammatory macrophage immunity. And a theoretical basis is provided for developing non-invasive, convenient and safe treatment of chronic inflammatory diseases such as rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Cited By

  • Yeast microcapsule delivery BBR / EGCG probiotic preparation and application

    CN120324365A